Will the Phase 2 trial "JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma" reach primary completion on or before Apr 6, 2027?

Resolves Yes if ClinicalTrials.gov record NCT07081022 (Shanghai Junshi Bioscience Co., Ltd.) shows an actual primary completion date on or before Apr 6, 2027. Registered date at generation: Apr 6, 2027.

Outcome verified from clinicaltrials.gov.

1. Market open

   Jul 17, 2026, 7:40 AM UTC
2. Market closes

   By Apr 6, 2027, 11:59 PM UTC
3. Projected payout

   Shortly after the market closes

Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.